[A clinical-electroneuromyographic study of the efficacy of ipidacrine in patients with mononeuropathies].

Abstract

OBJECTIVE:

To evaluate the efficacy and tolerability of axamon (ipidacrine) therapy in patients with focal neuropathies--mononeuropathies.

MATERIAL AND METHODS:

We examined 35 patients, aged 18 years and older, with focal neuropathies (tunnel syndromes, radiculopathies). In the main group (n=20) axamon (ipidacrine) was prescribed in addition to the basic (standard) therapy (group B vitamins, lipoic acid) during 6 week, in the control group (n=15) patients remained only on the basic (standard) treatment.

RESULTS:

In the main group positive clinical changes were accompanied by the more significant positive electroneuromyographic (ENMG) dynamics as compared to the control group (the increased amplitude of M-response in the muscles of the hand and feet; increased nerve conduction velocity in the peripheral nerves as a manifestation of remyelination activity, and others).

CONCLUSION:

The obtained clinical and ENMG data indicate that axamon (ipidacrine) is a unique cholinesterase inhibitor with conduction action primarily targeting on efferent (motor) fibers of the peripheral nerves.

• Authors: G N Avakyan, G G Avakyan
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 115 Issue 9 Pg. 17-22 ( 2015) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 26525809 (Publication Type: Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Aminoquinolines
• Cholinesterase Inhibitors
• Vitamin B Complex
• Thioctic Acid
• amiridine

Topics

• Aminoquinolines (therapeutic use)
• Cholinesterase Inhibitors (therapeutic use)
• Drug Therapy, Combination
• Electromyography
• Female
• Humans
• Male
• Mononeuropathies (drug therapy, physiopathology)
• Muscle, Skeletal (physiopathology)
• Thioctic Acid (therapeutic use)
• Vitamin B Complex (therapeutic use)